Анестезиологическое обеспечение при травматологической операции у пациентки с терминальной стадией хронической почечной недостаточности, находящейся на программном гемодиализе (клинический случай и обзор литературы)

В. І. Борисова, С. О. Дубров, В. Н. Лянскорунский

Анотація


В практике врача-анестезиолога могут быть случаи необходимости оказания анестезиологического обеспечения пациентам с сопутствующей терминальной стадией хронической почечной недостаточности, находящимся на программном гемодиализе. Осложнения, связанные с самой хронической почечной недостаточностью, а также с проведением гемодиализа влияют на выбор способа анестезии, равно как и на течение наркоза и послеоперационного периода.

В работе представлен обзор литературы патофизиологических изменений органов и систем у пациентов с хронической болезнью почек. Приведен клинический случай проведения оперативного вмешательства пациентке Ф., 82 лет с терминальной стадией хронической болезни почек, находящейся на програмированном диализе – выполнение металоостеосинтеза проксимального отдела правой бедренной кости.


Ключові слова


хроническая болезнь почек; заместительная почечная терапия; программный гемодиализ; гемостаз; тромбэмболизм; гипокоагуляция; артериальная гипертензия; ишемическая болезнь сердца; анестезиологическое обеспечение

Повний текст:

PDF (Русский)

Посилання


Бильченко, А. В. Хронические болезни почек и сердечно-сосудистые заболевания. Cистемный подходк терапии / А. В. Бильченко // Мистецтво лiкування. – 2009 No4. – С. 32 – 38.

Ватутин, Н. Т. Некоторые аспекты клинического применения рекомбинантного эритропоэтина / Н. Т. Ватутин, Н. В. Калинкина, А.Н. Шевелец // Внутренняя медицина. – 2008. – No 4( 10).

Гусева, С. А. Анемии при хронической почечной недостаточности / С. А. Гусева, Я. П. Гончаров // – Киев: Логос. – 2004. – С. 222 – 223.

Зуєв, К. О. Уротензин II — нова сходинка в розумiннi патогенезу кардiоваскулярної, ендокринної та ниркової патологiї / К. О. Зуєв // Мiжнародний ендокринологiчний журнал. – 2006. – No 3(5) . – С. 13 – 18.

Кардiоваскулярнi ускладнення у хворих на хронiчну хворобу нирок / М. О. Колеснiк [та iн.] // Київ, 2010. – 222 с.

Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями / И. Е. Чазова [и др.] // Кардиологический вестник. – 2014. – Вып. 1. – С. 3–57.

Руководство по кардиологии / М. И. Лутай [и др.]; под ред. В. Н Коваленко. – К.: Морион, 2008. – 1424 с.

Суслов, В. В. Особенности анестезии и интенсивной терапии при аллотрансплантации почки / В. В. Суслов, С. Н. Гриценко //Український журнал екстремальної медицини iменi Г.О. Можаєва. – 2012. – Т. 13, No 2. – С. 34 – 39

Ando M., Iwata A., Ozeki Y. et al. Circulated platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients // Kidney Int. –2002. – 62(5). – 1757 – 1763.

Andrew S. Bomback. Disordered aldosterone-volume relationship in end-stage kidney disease / Andrew S. Bomback, Abbijit V. Ksbirsagar, Maria I. Ferris et al. // Jornal of the Renin-Angiotensin-Aldosterone System. – 2009. – Vol. 10. – No4. – P. 229 – 237.

Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure //Semin. Thromb. Hemost. – 2004. – Vol. 30. – P. 579 – 589.

Bonomini M., Dottori S., Amoroso L. et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia // J. Thromb. Haemost. – 2004. – Vol. 2. P 1275 –1281.

Brunini T.M., Mendes-Ribeiro A.C., Ellory J.C. et al. Platelet nitricoxide synthesis in uremia and malnutrition: a role for L-arginine supplementation in vascular protection? // Cardiovasc. Res. – 2007. – Vol. 73. – P. 359 – 367.

Caglar K., Peng Y., Pupim L.B. et al. Inflammatory signals associated with hemodialysis // Kidney Int. –2002 – 62(4). – 1408 – 1416.

Cai Q., Mukku V.K., Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update.// Curr. Cardiol. Rev. – 2013. – 9(4). – 331 – 9.

Camaioni C., Gustapane M., Cialdella P. et al. Microparticles and microRNAs: new players in the complex field of coagulation // Intern. Emerg. Med. – 2011. –8(4). – 291 – 296.

Cetin O., Bekpinar S., Unlucerci Y. et al. Hyper-homocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation // Clin. Nephrol. – 2006. – Vol. 65. – P. 97 – 102.

D’Elia J. A., Weinrauch L. A., Gleason R. E. et al. Risk factors for thromboembolic events in renal failure // Int. J. Cardiol. – 2005. – 101(1). – 19 – 25.

Dager W. E., Kiser T. H. Systemic anticoagulation considerations in chronic kidney disease // Adv. Chronic. Kidney Dis. – 2010. Vol. 17. – P. 420 – 427.

Daniel L., Dou L., Berland Y. et al. Circulating microparticles in renal diseases // Nephrol. Dial. Transplant. – 2008. – Vol. 23. – P. 2129 – 2132.

Davina J. Tai. Cardiovascular effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis / Davina J., Thomas W. Lim, Matthew T. James et al. // C. J. Am. Nephrol. – 2010. – Vol. 5. – No4. – P. 623 – 630.

Doulton, Timothy W. R. Blood pressure in haemodialysis patients: The importance of the relationship between the renin-angiotensin-aldosterone system, salt intake and extracellular volume / Timothy W. R. Doulton, Graham A. MacGregor // Jornal of the Renin-Angiotensin-Aldosterone System. – 2004. – Vol. 5. – No 1. – P. 14 – 22.

Drawz P. E., Rosenberg M. E. Slowing progression of chronic kidney disease // Kidney Int. Suppl. Int. Society of Nephrology. – 2013. – 3(4). – 372 – 376.

European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. // J. Hypertens. – 21(6). – 1011– 1053.

Fagugli, R. M. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patient / Riccardo Maria Fagugli, Paolo Pasini, Guseppe Quintaliani, Franca Pasticci // Nephrol. Dial. Transpl. – 2003. – Vol. 18(11). – P. 2332 – 2338.

Fareed J., Leong W. L., Hoppensteadt D. A. et al. Generic low-molecularweight heparins: some practical considerations // Semin. Thromb. Hemost. – 2004. – 30(6). – 703 – 713.

Fine L. G., Norman J. T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics // Kidney Int. – 2008. – 74(7). – 867 – 872.

Fole y R. N. Effect of hemoglobin levels in he modialysis patient swith a symptomatic cardiomyopathy / Foley R.N., Parfrey P.S., Morgan J. // Kidney Intern. – 2000. – Vol. 58. – P. 1325 – 1335.

Folsom A. R., Lutse y P. L., Astor B. C. et al. Chronic kidney disease and venousthromboembolism : a prospective study // Nephrol. Dial. Transplant. – 2010. – Vol. 25. – P. 3296 – 3301.

Galbusera M., Remuzzi G., Boccardo P. Treatment of bleeding in dialysis patients // Semin. Dial. – 2009. – Vol. 22. – P. 279 – 286.

Glorieux G., Cohen G., Jankowski J. et al. Platelet/ leukocyte activation, inflammation, and uremia // Se min. Dial. –2009. – Vol. 22. – P. 423 – 427.

Go A. S., Chertov G. M., Fan D. et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. – 2004. – Vol. 351. – P. 1296 – 1305.

Gradaus F., Ivens K., Peters A. J. et al. Angiographic progression of coronary artery disease in patients with end-stagerenal disease // Nephrol. Dial Transplant. – 2001. – 16 (6). – 1198-202.

Guidelines for the management of arterial hypertension: The Task Force for themanagement of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) /Giuseppe Mancia [ et al.] // European Heart Journal. – 2013. – Vol. 34, I ssue 28. – P. 2159 – 2219.

Herzog C. A., Asinger R. W., Berger A. K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)//Kidney Int. – 2011. – 80(6). – 572 – 86.

Himmelfarb J., Henrich W., DuBose T. Anemia of Kidney Disease and Clinical Practice Guidelines: Quo Vadis? // Clin. J. Am. Soc. Nephrol. – 2007. – No 2. – P. 213-214.

Hirsh et al. and Kearonetal. Chest 2008 8th ACCP Conference on Antithrombotic and Thrombolytic Therapy – 2008.

Jalal D. I., Chonchol M., Targher G. Disorders of hemostasis associated with chronic kidney disease // Semin. Thromb. Hemost. – 2010. – 36(1). – 34–40.

Kohadura K. Plasma aldosterone in hypertensive patients on chronic haemodialysis: distribution, determinants and impactin survival / Kohadura K., Higashiuesato Y., Ishiki T. еt al. // Hypertens Res. – 2006. – 29. – 596 – 604.

Lim W., Dentali F., Eikelboom J. W., Crowter M. A. Metaanaly sis: lowmolecular- weigh the parin and bleeding in patients with severerenal insufficiency // Ann. Intern. Med. – 2006. – 144(9).– 673–684.

Lundgren E. Metabolic abnormalities in patient with normocalcemic hyperparathyroidism detected at a population-based screening / Lundgren Е. // Europian Journal of Endocrinology. – 2006. – Vol. 259. – No 2. – P. 196 – 198.

Mezzano D., Pais E. O., Aranda E., et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia // Kidney Int. – 2001. – Vol. 60. – P. 1844 – 1850.

Moal V., Brunet P., Dou L. et al. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients // Nephrol. Dial. Transplant. – 2003. – Vol. 18. – P. 1834 – 1841.

Molino D., de Lucia D., Gaspare de Santo N. Coagulation disorder sinuremia // Semin. Nephrol. – 2006. – Vol. 26. – P. 46 – 51.

Morse, Stephen A. Hypertension in Chronic Dialysis Patients: Pathophysiology, Monitoring, and Treatment / Morse, Stephen A., Dang, An, Thakur, Vashu et al. // Am. J. Med. Sciences. – 2003. – Vol. 325, Issue 4. – P. 194 – 201.

National Kidney Foundation. KDOQI Clinical Practice Guide lines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. // Am. J. Kidney Dis. – 2006. – Vol. 48. – P. 1 – 322.

Ocak G., Verduijn M., Vossen C. Y. et al. Chronic kidney disease stages 1–3 increase the risk of venous thrombosis // J. Thromb. Haemost. – 2010. – Vol. 8. – P. 2428 – 2435.

Ohtake T., Kobayashi S., Moriya H., et al. High Prevalence of Occult Coronary Artery Stenosis in Patients with Chronic Kidney Disease at the Initiation of Renal Replacement Therapy: An Angiographic Examination // J. Am. Soc. Nephrol. – 2005. Vol. 16. – P. 1141 – 1148.

Ovcharenko E. Renal effects of human urotensin II in rats with experimental heart failure / Ovcharenko E., Abassi Z., Rubinstein I. et al. // Nephrol. Dial. Transplant. – 2006. – Vol. 21. – P. 1205 – 1211.

Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease // Blood Rev. – 2011. – Vol. 25. – P. 271 – 278.

Pawlak K., Tankiewicz J., Mysliwiec M. et al. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment // Blood Coagul. Fibrinolysis. – 2009. – Vol. 20. – P. 590 – 594.

Rao M. V, Qiu Y., Wang C., Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 // Am. J. Kidney Dis. – 2008. – Vol. 51. – P. 30 – 37.

Rimoldi S. F., Scherrer U., Messerli F. H. Secondary arterial hypertension: when, who, and how to screen? // Eur. Heart J.–2013. – 35(19). – 1245–1254.

Schmid P., Fisher A. G., Wuillemin W. A. Low-molecular-weight heparin in patients with renal insufficiency // Swiss Med. WKLY. – 2009. – 139(31–32). – 438–452.

Sela-Brown A . Regulation parathyroid hormone, gen byvit. D, calcium and phosphate / Sela-Brown А. // Kidney Int. J. – 2005. – Vol. 56. – No7. – P. 2 – 7.

Sharma R., Pellerin D., Gaze D. C., et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renaltransplantc and idates // Nephrology Dialysis Transplantation. – 2005. – 20(10). – 2207-14.

Shlipak M. G., Fried L. F., Crump C. et al. Elevations of in flammatory and procoagulant biomarker sinelderly persons with renal insufficiency // Circulation. – 2003. – Vol. 107. – P. 87 – 92.

Sirolli V., Ballone E., di Stante S. et al. Cell activation and cellular- cellular interactions during hemodialysis: effect of dialyzer membrane // Int. J. Artif. Organs. – 2002. – Vol 25. – P. 529 – 537.

Tay K. H., Lip G. Y. What «drives» the link between the renin-angiotensin- aldosterone system and the prothrombotic state in hypertension? // Am. J. Hypertens. – 2008. – Vol. 21. – P. 1278 – 1279.

Thekkedath U. R., Chirananthavat T., Leypoldt J. K. et al. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprote in IIb–IIIa // Am. J. Hematol. – 2006. – Vol. 81. – P. 915 –926.

Wadei H. M., Textor S. C. The role of the kidney in regulating arterial blood pressure // Nat. Rev. Nephrol. – 2012. – 8(10). – 602 – 609.

Wattanakit K., Cushman M., Stehman-Breen C. et al. Chronic kidney disease in creases risk for venous thromboembolism // J. Am. Soc. Nephrol. – 2008. – Vol. 19. – P. 135 – 140.

Wattanakit K., Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms // Curr. Opin. Pulm. Med. – 2009. – Vol. 15. – P. 408 – 412.

Zoccali C. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease / Zoccali C., Mallamaci F. // Circulation. – 2002. – Vo l. 105. – P. 1354 – 1359.


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.25284/2519-2078.2(83).2018.135827

Посилання

  • Поки немає зовнішніх посилань.




Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Асоціація анестезіологів України, 1997-2017. ISSN 2520-226X (Online), ISSN 2519-2078 (Print).

Flag Counter